Objectives: Caspofungin and micafungin belong to the echinocandins; the mechanism of action of echinocandins is based on the inhibition of (1,3)-b-D-glucan synthase. The aim of this study was to investigate in vitro the optimal antifungal lock treatment details against a Candida albicans biofilm.
Introduction
Candidaemia is frequently associated with intravascular catheterrelated infection that causes increased morbidity, mortality and healthcare costs. These infections are associated with the formation of a biofilm consisting of sessile fungi, a hyphal layer and an extracellular matrix. The fungal biofilm alters the susceptibility to antifungal agents, 1 and once infected, the current clinical procedure is the removal of the catheter and the administration of systemic antifungals. 2 Conservative strategy of the catheter in candidaemia, including lock and systemic therapies, could be adopted in clinically stable patients to avoid intravascular catheter replacement. 3 This hypothesis proceeds from investigations carried out in the case of the evaluation of lock technique for the treatment of catheter-related bacteraemia. 4 The antibiotic-lock technique involves the static instillation of a concentrated solution of antibiotic into the catheter lumen and allowing it to remain for an extended period, usually 12 h. 4 Echinocandins have been recently approved for use in the treatment of candidiasis and their mechanism of action is based on the inhibition of (1,3)-b-D-glucan synthase, which is responsible for forming glucan polymers in the cell wall. The in vitro anti-biofilm activity of echinocandins has been previously demonstrated. 1,5 -7 However, the potential of echinocandins used as lock therapy is very poorly documented.
This study deals with the in vitro anti-biofilm potential of two echinocandins, caspofungin and micafungin, used as a lock solution to manage Candida albicans biofilms.
Materials and methods
In this study, biofilms of C. albicans strains ATCC 66396 and 3153, 12 h and 5 days old, respectively, were formed in microtitre plates, as described previously, using sections of 100% silicone catheters (A-M Systems, Carlsborg, WA, USA). 6 The tested concentrations of caspofungin and micafungin were about 100 times MIC and so were compatible with a lock therapy strategy. 4 Antifungal solutions were diluted in YNB-Glc (6.7 g of YNB, 5 g of Glc and 1 L of water). Aliquots (300 mL) of 2 mg/L caspofungin (Merck Research Laboratories, Rahway, NJ, USA) or 5 mg/L micafungin (Astellas Pharma Inc., Tokyo, Japan) were then added to the biofilms, and plates were incubated for 12 h at 378C. For controls, biofilms were incubated for 12 h with 300 mL of YNB-Glc. All the silicone pieces were then moved into new wells of the plate and incubated with YNB-Glc without antifungal, at 378C for 24, 48 or 72 h, to evaluate the persistence of the anti-biofilm activity of echinocandins.
Echinocandin effects were monitored by a previously described metabolic assay based on the reduction of a tetrazolium salt (XTT). 6, 8 Briefly, each catheter section coated with biofilm and treated or not with antifungal was incubated for 3 h at 378C with XTT (300 mg/L) and menadione (0.13 mM) in 150 mL of PBS. Absorbance was then measured at 492 nm (microplate reader LP400, Sanofi Diagnostics Pasteur) and correlated with the yeast metabolic activity within the biofilm. All experiments were performed twice with eight replicates. An analysis of variance and a Scheffe's test were conducted to determine the statistical differences between groups.
Results and discussion
The biofilm growth inhibition observed after such a lock treat- (Figure 1b) . These results showed that caspofungin and micafungin used in our experimental conditions demonstrated an inhibitory activity of 70% on a 12 h old biofilm development, 24 h after the lock therapy, for the two studied strains. Furthermore, this anti-biofilm efficacy was maintained after the end of the lock, suggesting a persistence of the activity. To confirm and investigate this persistence, the 12 h old biofilm (strain 3153 or 66396) growth inhibition was also evaluated 48 or 72 h after the end of each echinocandin lock.
For the 3153 strain, even 48 h after the end of the lock, caspofungin and micafungin demonstrated a significant activity on the development of a 12 h old biofilm, ranging from 54% (micafungin) to 85% (caspofungin), as shown by absorbance values: control: A 492 ¼ 0.536; caspofungin: A 492 ¼ 0.082 and micafungin: A 492 ¼ 0.245 (Figure 1a) . Whereas 72 h after the end of the lock, the inhibition observed was~40% with caspofungin or micafungin (control: A 492 ¼ 0.517; caspofungin: A 492 ¼ 0.312 and micafungin: A 492 ¼ 0.309; Figure 1a) .
For the 66396 strain, the anti-biofilm activity also seemed to be maintained. Our investigations have shown that 48 h after the end of the treatment, the observed growth inhibition was 60% with caspofungin (control: A 492 ¼ 0.735 and caspofungin:
A 492 ¼ 0.292) and 93% with micafungin (micafungin: A 492 ¼ 0.054). Three days after the end of the antifungal contact, the inhibition percentages were 57% and 52%, respectively, control: A 492 ¼ 0.670; caspofungin: A 492 ¼ 0.286 and micafungin: A 492 ¼ 0.319 (Figure 1b) .
In conclusion, these results confirmed that the anti-biofilm activity of the two echinocandins on intermediate C. albicans biofilms is persistent, even if 72 h post-lock, the inhibition seemed to decrease: echinocandin locks did not manage to induce more than a reduction by half of the metabolic activity of the biofilms 72 h after the end of the antifungal contact.
In the second part of this work, we investigated the efficiency of these locks on the development of a mature C. albicans biofilm, i.e. 5 days old. The activity persistence was tested 24 or 48 h after the end of each lock. The persistence 72 h after the treatment was not evaluated because we hypothesized that the activity decrease observed with an intermediate biofilm would have been intensified on older biofilms.
On a 5-day-old C. albicans 3153 biofilm, the inhibition observed 24 h after the end of the lock was 87% for caspofungin (control: A 492 ¼ 0.608 and caspofungin: A 492 ¼ 0.079) and 58% for micafungin (micafungin: A 492 ¼ 0.230) (Figure 1a ). For the 66396 strain, in the same conditions, the inhibition was 90% for caspofungin (control: A 492 ¼ 0.667 and caspofungin: A 492 ¼ 0.067) and 89% for micafungin (micafungin: A 492 ¼ 0.075) (Figure 1b) . Therefore, the anti-biofilm activity described for the intermediate biofilm treated by the studied echinocandins used as lock solutions was verified on older biofilms whatever the studied strain.
The results obtained from these mature biofilms 48 h after the end of the contact corroborated the hypothesis that the activity of echinocandins used as lock solutions was persistent. For the 3153 strain, the inhibition was 88% for caspofungin 
Conclusions
Our results underlined the in vitro ability of lock solutions to reduce the metabolic activity of a C. albicans biofilm, whatever the echinocandin used and whatever the biofilm maturation stage, within the limits of the experimental conditions of this study. In addition, our results showed no acquisition of resistance, suggesting that echinocandins could be of interest in the management of candidiasis associated with catheters. Our results agreed with previous investigations that had already shown that caspofungin and aminocandin, another echinocandin, were capable of anti-adherent and anti-biofilm activity. 6, 9 These experiments were different from the presented lock methodology because the metabolic activity of the biofilm was evaluated as soon as the antimicrobial treatment was over.
In conclusion, our results showed that in vitro, caspofungin and micafungin managed at least to reduce by half the metabolic activity of C. albicans growing as a biofilm. However, all results corroborated the hypothesis that echinocandins would have a real anti-biofilm potential and could become important factors in the lock approach. The tested concentrations corresponded to the lowest concentrations that can be used as a lock strategy, if we consider antibiotic lock therapy data. 4 The use of higher echinocandin concentrations could be considered, but Melo et al.
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have recently described an in vitro paradoxical effect using supra-MIC concentrations of caspofungin, suggesting that experimental conditions have to be monitored carefully. Our study suggests that the lock therapy strategy could be extended to fungal infections. 
